Dual anti-HER2/EGFR inhibition synergistically increases therapeutic effects and alters tumor oxygenation in HNSCC is a research paper published in Scientific Reports (2024). On theSindex it has a DataRank of 0. It has been cited 13 times.
Scored on demand from live citation data
Linked data & code
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
National Institutes of Health
Grant: T32GM135028
National Institutes of Health
Grant: R01CA240589
American Cancer Society
Grant: RSG-18-006-01-CCE
NCI NIH HHS
Grant: R01 CA276540
NCATS NIH HHS
Grant: TL1 TR003106
NIBIB NIH HHS
Grant: T32 EB023872
NCI NIH HHS
Grant: P30 CA013148
National Institutes of Health
Grant: 5R01CA240589-04
Personalizing immunotherapy in HER2+ breast cancer through quantitative imaging
National Institutes of Health
Grant: 1R01CA276540-01
Mathematical modeling and molecular imaging to maximize response while minimizing toxicities from systemic therapies in preclinical models of breast cancer
National Institutes of Health
Grant: 2P30CA013148-34
TISSUE PROCUREMENT
National Institutes of Health
Grant: 5T32GM135028-03
UAB Predoctoral Training Grant in Translational and Molecular Sciences
Fields of Study
MeSH Terms
Keywords
Sustainable Development Goals
Additional file 1 of The efficacy and potential mechanisms of pyrotinib in targeting EGFR and HER2 in advanced oral squamous cell carcinoma
Additional file 1 of The efficacy and potential mechanisms of pyrotinib in targeting EGFR and HER2 in advanced oral squamous cell carcinoma